Pharvaris (NASDAQ:PHVS) Trading Up 5.1%

Pharvaris (NASDAQ:PHVS) rose 5.1% on Monday . The company traded as high as $17.14 and last traded at $17.00. 52,495 shares changed hands during trading, a decline of 37% from the average session volume of 82,686 shares. The stock had previously closed at $16.18.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on PHVS shares. Wedbush decreased their target price on Pharvaris from $35.00 to $31.00 and set an “outperform” rating for the company in a report on Thursday, May 9th. Oppenheimer boosted their price target on shares of Pharvaris from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 3rd. Morgan Stanley reaffirmed an “overweight” rating and set a $34.00 price objective on shares of Pharvaris in a research note on Monday, April 22nd. Finally, JMP Securities lifted their target price on Pharvaris from $49.00 to $50.00 and gave the stock a “market outperform” rating in a research report on Thursday, April 11th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $32.80.

Pharvaris Stock Up 6.4 %

The stock has a market cap of $548.28 million, a P/E ratio of -6.25 and a beta of -3.10. The business’s 50-day simple moving average is $17.91 and its two-hundred day simple moving average is $22.13.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.56) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.56). Analysts anticipate that Pharvaris will post -2.39 earnings per share for the current fiscal year.

Institutional Trading of Pharvaris

Large investors have recently added to or reduced their stakes in the stock. Blackstone Inc. purchased a new stake in Pharvaris in the fourth quarter worth about $2,805,000. Vivo Capital LLC purchased a new position in shares of Pharvaris in the 4th quarter valued at approximately $7,994,000. Commodore Capital LP bought a new stake in shares of Pharvaris during the fourth quarter valued at approximately $22,440,000. Finally, venBio Partners LLC grew its stake in Pharvaris by 15.4% in the fourth quarter. venBio Partners LLC now owns 4,919,504 shares of the company’s stock worth $137,992,000 after purchasing an additional 654,832 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.